XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 Latest Research
 Infectious Diseases
 Respiratory Medicine
  Cystic Fibrosis
 Public Health
 Clinical Trials
 Medical News
 Awards & Prizes
 Special Topics
 Odd Medical News
 World News

Last Updated: Nov 17th, 2006 - 22:35:04

Asthma Channel
subscribe to Asthma newsletter

Latest Research : Respiratory Medicine : Asthma

   DISCUSS   |   EMAIL   |   PRINT
Montelukast significantly reduced Asthma exacerbations in young children
Feb 16, 2005, 19:33, Reviewed by: Dr.

Montelukast, a leukotriene receptor antagonist, significantly decreased the rate of exacerbations and lengthened the time between exacerbations in 2- to 5-year-old asthma patients who suffered from intermittent symptoms. The researchers pointed out that montelukast significantly reduced by almost 32 percent the rate of exacerbations over 12 months, as compared with results from patients on placebo. The average rate of exacerbation episodes was 1.60 episodes per patient per year, compared with 2.34 for placebo. (Leukotrienes are biologically active compounds that function as chemical mediators. They have vasoactive properties that help regulate allergic and inflammatory reactions. Medical antagonists are designed to counteract specific functions.) According to the authors, asthma usually begins and has its greatest prevalence in children younger than 5 years.

This age group often has intermittent symptoms, which include long assymptomatic periods interrupted by episodes of asthma generally in association with the common cold. Viral infections, predominately with rhinovirus, account for up to 85 percent of childhood asthma exacerbations and daily symptoms. The investigators claim that there are usually minimal symptoms between episodes. The 1-year study directed at exacerbation control was conducted at 68 sites in 23 countries. It involved 278 children receiving low-dose montelukast once a day for 12 months, along with 271 young participants receiving placebo. According to the authors, montelukast delayed the median time to first exacerbation by approximately 2 months. It also significantly reduced the overall rate of corticosteroid use by almost 32 percent and the rate of inhaled corticosteroid use by almost 40 percent. However, although the use of montelukast reduced exacerbations in intermittent asthma, the investigators said that they do not necessarily advocate year-round regular treatment with the compound. They noted that since exacerbations tended to be seasonal, therapy should begin before the viral season when the exacerbation rate is high.

- American Thoracic Society Journal

American Thoracic Society Online Web Site

Subscribe to Asthma Newsletter
E-mail Address:


Related Asthma News

A dog in home may worsen asthma in children
PEAK Trial: Inhaled steroids do not prevent chronic asthma
Telithromycin antibiotic could help in asthma attack
Tomatoes, carrots can cut asthma risk
Inhaled steroid may work better for normal-weight people
Female foetus could increase expectant woman's asthma
Childhood Asthma Affecting More than Just Breathing
Omalizumab has long-term benefits in severe allergic asthma
CD23 structure revealed by NMR spectroscopy
Bacteria in Household Dust May Trigger Asthma

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page


© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us